



## Lipid-Based Nanocarriers in Drug Delivery and Theranostic Applications

Guest Editors:

**Prof. Dr. Rosario Pignatello**

1. Department of Drug and Health Sciences, University of Catania, Catania, Italy;  
2. NANOMED-Research Centre on Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, Catania, Italy

**Prof. Dr. Claudia Carbone**

1. Department of Drug and Health Sciences, University of Catania, Catania, Italy  
2. NANOMED-Research Centre on Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, Catania, Italy

Deadline for manuscript submissions:

**closed (25 July 2024)**

### Message from the Guest Editors

Lipid-based nanocarriers are a wide group of pharmaceutical systems by which drug delivery through various administration routes is being constantly exploited. The attention of researchers and companies towards these kinds of carriers is mainly linked to their composition, based on natural or synthetic highly biocompatible and non-toxic lipid ingredients, with the consequent benefits in terms of regulatory issues, to the easily scalable production methods, and to the possibility of modulating their stability and distribution to specific sites in the body through the bio-chemical modification of surface. LNs can be functionalized with different targeting moieties and possess the potential to cross different physiological barriers, hence improving pharmacokinetics.

This Special Issue aims to update the latest research on lipid-based formulations of therapeutics, including but not limiting to solid lipid nanoparticles, nanostructured lipid carriers, drug-lipid conjugates, hybrid nanoparticles, liposomes, and nanoemulsions, both from a technological point of view as well as at preclinical and clinical levels. Original experimental works and review manuscripts are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Amélia Pilar Rauter**

Departamento de Química e  
Bioquímica (DQB) e Centro de  
Química Estrutural (CQE),  
Institute of Molecular Sciences,  
Faculdade de Ciências,  
Universidade de Lisboa, Lisboa,  
Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)